Disappointing BRAVO Data Raise Doubts About Laquinimod’s Chances
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Teva Pharmaceuticals Co. Ltd. is facing investor doubts about regulatory prospects for its oral multiple sclerosis drug laquinimod after the drug missed the primary endpoint in a second Phase III trial, called BRAVO.